Technology evaluation: APC-80200, Dendreon.
APC-80200 (Mylovenge) has been developed for the treatment of B-cell malignancies and is currently in phase II clinical trials as a therapeutic vaccine for patients with advanced multiple myeloma. This vaccine candidate appears to be of particular benefit in patients who have received high-dose chemotherapy to reduce tumor load following stem cell rescue. APC-80200 is also being tested in patients with amyloidosis.
Rice
Alison
A
Mater Medical Research Institute, South Brisbane, Queensland, Australia.
Hart
Derek
D
D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*; D013673:Technology Assessment, Biomedical
D019496:Cancer Vaccines